Breaking News, Collaborations & Alliances

Taysha Gene Therapies Partners with Catalent

Rapidly expands Taysha’s manufacturing capacity.

By: Contract Pharma

Contract Pharma Staff

Taysha Gene Therapies Inc., a patient-centric gene therapy company focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system, and Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, have partnered to support the development and manufacturing of Taysha’s gene therapie...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters